GSK acquires biotene dry mouth products

GlaxoSmithKline Consumer Healthcare has acquired the complete range of biotène branded products indicated in the treatment of xerostomia (dry mouth) from privately held US company Laclede. Xerostomia is a significant health issue associated with chronic medical conditions that include diabetes, rheumatoid arthritis, Sjogren's syndrome and Parkinson's disease. Additionally, chemotherapy and radiation treatments together with more than 400 known medications have side-effects that can cause Dry Mouth. The products are also used by mouth breathers. The biotène system has been appropriately formulated to relieve dry mouths. Each product contains the biotène salivary LP3 enzyme system, is alcohol-free, sugar-free and sodium lauryl sulphate-free. biotène also contains moisturisers and lubricants to provide relief from the symptoms of dry mouth. The biotène range consists of toothpaste, mouthwash, gel, liquid, mouth-spray and chewing gum. The range provides both in-home hygiene products and out-of-home relief products for the dry mouth patient.

To purchase biotène products, dental practices should contact distributor Critical Dental.